Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vernakalant IV PDUFA date extended

Astellas (Tokyo:4503) and Cardiome (TSX:COM; CRME) said FDA requested additional safety and efficacy

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE